{
"@context": "https://schema.org",
"@type": "Article",
"headline": "OIG Report on Topical Compounded Drug Prescribing, Marketing and Billing Practices Signals Heightened Administrative and Enforcement Scrutiny",
"url": "https://www.lexblog.com/2018/11/02/drug-pricing-medicare-part-d-2/",
"identifier": {
"@type": "PropertyValue",
"name": "LexBlog Library record",
"value": "LEX-WK-6GJ2CW7H",
"url": "https://www.lexblog.com/lib/6GJ2CW7H/"
},
"datePublished": "2018-11-02T14:39:01-04:00",
"dateModified": "2021-02-10T14:44:42-05:00",
"author": {
"@type": "Person",
"name": "Kathleen Stratton"
},
"sourceOrganization": {
"@type": "Organization",
"name": "Sheppard, Mullin, Richter & Hampton LLP"
},
"organizationScope": "at-publication",
"isPartOf": "Organizational Integrity Group Blog",
"about": "Other",
"sourceUrl": "https://www.fcadefenselawblog.com/?p=1538",
"sourceStability": "may-move"
}